Department of Internal Medicine, Respiratory Medicine Section, Herlev and Gentofte Hospital, Copenhagen University Hospital, Hellerup, Denmark.
Department of Respiratory Medicine, Amager and Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
BMJ Open Respir Res. 2019 Mar 30;6(1):e000407. doi: 10.1136/bmjresp-2019-000407. eCollection 2019.
A large group of patients with chronic obstructive pulmonary disease (COPD) are exposed to an overload of oral corticosteroids (OCS) due to repeated exacerbations. This is associated with potential serious adverse effects. Therefore, we evaluated the impact of a recommended reduction of OCS duration in 2014 on the risk of pneumonia hospitalisation and all-cause mortality in patients with acute exacerbation of COPD (AECOPD).
This was a nationwide observational cohort study that was based on linked administrative registry data between 1 January 2010 and 31 October 2017. 10 152 outpatients with COPD (median age 70 years) treated with either a short (≤250 mg) or long course (>250 mg) of OCS for AECOPD were included in the study. Cox proportional hazards regression models were used to derive an estimation of multivariable adjusted HRs (aHRs) for pneumonia hospitalisation or all-cause mortality combined and pneumonia hospitalisation and all-cause mortality, separately.
The long course of OCS treatment for AECOPD was associated with an increased 1-year risk of pneumonia hospitalisation or all-cause mortality (aHR 1.3, 95% CI 1.1 to 1.4; p<0.0001), pneumonia hospitalisation (aHR 1.2, 95% CI 1.0 to 1.3; p=0.0110) and all-cause mortality (aHR 1.8, 95% CI 1.5 to 2.2; p<0.0001) as compared with the short course of OCS treatment. These results were confirmed in several sensitivity analyses.
The change of recommendations from long courses to short courses of OCS for AECOPD in 2014 was strongly associated with a decrease in pneumonia admissions and all-cause mortality, in favour of short courses of OCS.
由于反复恶化,大量慢性阻塞性肺疾病(COPD)患者暴露于口服皮质类固醇(OCS)的超负荷中。这可能会产生潜在的严重不良反应。因此,我们评估了 2014 年推荐减少 OCS 疗程对 COPD 急性加重(AECOPD)患者肺炎住院和全因死亡率的影响。
这是一项全国性的观察性队列研究,基于 2010 年 1 月 1 日至 2017 年 10 月 31 日期间的行政登记数据进行链接。研究纳入了 10152 例接受 COPD 治疗的门诊患者(中位年龄 70 岁),这些患者因 AECOPD 接受了短(≤250mg)或长(>250mg)疗程的 OCS。使用 Cox 比例风险回归模型来计算肺炎住院或全因死亡率综合以及肺炎住院和全因死亡率单独的多变量调整风险比(aHR)的估计值。
AECOPD 中 OCS 的长疗程治疗与 1 年肺炎住院或全因死亡率风险增加相关(aHR 1.3,95%CI 1.1 至 1.4;p<0.0001)、肺炎住院(aHR 1.2,95%CI 1.0 至 1.3;p=0.0110)和全因死亡率(aHR 1.8,95%CI 1.5 至 2.2;p<0.0001),与 OCS 短疗程治疗相比。这些结果在几项敏感性分析中得到了证实。
2014 年,AECOPD 中从长疗程 OCS 改为短疗程 OCS 的建议改变与肺炎入院和全因死亡率的降低密切相关,有利于使用短疗程 OCS。